Effect of Prolonged Fasting Time on Gastric Residual Volume in Patients Taking GLP1 Receptor Agonists
Lead sponsor
Asset
GLP-1 / incretin class catch-all
Listed sites
1
Recruiting sites
1
Estimated enrollment
150
Study population
-
Eligibility highlights
-
Primary endpoint
•Gastric contents
Registered trial locations
Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.
Identifiers
Registered as
Timeline
Milestones
Assets
Investigational agents
Who can enroll
Inclusion criteria
Exclusion criteria
Endpoints (4)
What's being measured
Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.
Other (unclassified)
4 endpointsGastric contents
Time frame:Baseline
descriptive
Diagnosis of aspiration within 72 hours of procedure
Time frame:From the time of upper endoscopy until 72 hours post-procedure.
ratio, improvement
Aspiration pneumonitis diagnosis postoperatively
Time frame:72 hours after completion of upper endoscopy
ratio, improvement
Postprocedural ICU admission
Time frame:Immediately after upper endoscopy
descriptive
Provenance
Sources
Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.